Nephrodi Therapeutics, Inc

NephroDI Therapeutics is a Philadelphia-based pharmaceutical company dedicated to addressing concentration disorders of the kidney, with a particular focus on Nephrogenic Diabetes Insipidus (NDI) in children. Their team of experts, including Dr. Jeff Sands as Chief Medical Officer, is committed to developing innovative treatments for this rare genetic condition, which causes an inability of the kidney to concentrate urine normally in response to the hormone vasopressin.

By identifying a novel series of AMPK as a potential therapy, NephroDI Therapeutics aims to provide a first-in-class oral drug that can significantly improve the quality of life for children suffering from NDI. With the ultimate goal of preventing severe dehydration, mental retardation, and kidney damage, NephroDI Therapeutics is dedicated to addressing the unmet challenges faced by patients with this pediatric orphan disease.

Generated from the website